+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - UK

  • ID: 2654490
  • Report
  • Region: United Kingdom, Great Britain
  • 169 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3
CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - UK

Summary

The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in the UK. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of the UK. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis by Packaging’s team of industry experts.

The value of the UK pharmaceutical market increased from £13.2bn ($20.3bn) in 2010 to £19.6bn ($25.9bn) in 2017, at a compound annual growth rate (CAGR) of 5.9% in the terms of GBP and 3.5% in the terms of US$. The market is expected to reach £26.2bn ($30.9bn) in 2022. The increased usage of personalized medicines, incorporating digital technology into drug development and accelerating drug access pathway, high disease burden and rise in elderly population are the main driving factors of pharmaceutical market. In 2015, the medical device market in the UK was worth $17.8 billion, which increased to $19.1 billion in 2017 at a CAGR of 3.6%. It is expected to grow at a CAGR of 4.1% from $19.8 billion in 2018 to $26.3 billion in 2025. The main segments were in vitro diagnostics, ophthalmic devices, cardiovascular devices, wound care devices and orthopedic devices. The development in personalized or precision medicines, incorporation of genetic sequencing and personal genome data, is revolutionizing the approach medical practitioners and pharmaceutical industries are undertaking for the disease treatment.

Scope

The report provides information on the healthcare, regulatory, and reimbursement landscape in the UK, and includes -
  • An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers
  • Profiles and SWOT analyses of the major players in the pharmaceutical market (AstraZeneca, GlaxoSmithKline, Merck, Novartis and Pfizer) and profiles and SWOT analyses of the major players in the medical device market (Siemens, Roche, DePuy, Essilor and Smith & Nephew)
  • Detailed analysis about recent completed deals in the pharmaceutical and medical device market of the UK
  • Porter’s five forces analysis for pharmaceutical and medical devices market of the UK
  • An insightful review of the reimbursement and regulatory landscape, of which analysis includes details of the healthcare reimbursement process, the regulatory agencies and the approval processes for new drugs and medical devices
  • Information regarding recent healthcare policies along with healthcare infrastructure and healthcare expenditure
  • An overview of the opportunities for and challenges to growth in the UK healthcare market.
Reasons to Buy

This report will enhance your decision-making capability by allowing you to -
  • Develop business strategies by understanding the trends shaping and driving the UK healthcare market
  • Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments, and companies likely to impact the healthcare market in the future
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment, and strategic partnership
  • Identify, understand, and capitalize on the opportunities and challenges in the UK healthcare market.
Note: Product cover images may vary from those shown
2 of 3
Executive Summary
Overview of Pharmaceutical Market
Overview of Medical Device Market
Deals Analysis
Porter’s Five Forces Model
Market Access
Country Healthcare Landscape
Opportunities and Challenges
Appendix

List of Tables
Table 1: Pharmaceutical Market, UK, Sales of Patented Drug Products by Major Therapeutic Class ($bn), 2016
Table 2: Medical Device Market, UK, Revenue by Segment ($bn), 2017
Table 3: InVitro Diagnostics Devices Market, UK, Revenue and Market Share of Major Players
Table 4: Ophthalmic Devices Market, UK, Revenue and Market Share of Major Players
Table 5: Cardiovascular Devices Market, UK, Revenue and Market Share of Major Players
Table 6: Wound Care Devices Market, UK, Revenue and Market Share of Major Players
Table 7: Orthopedic Devices Market, UK, Revenue and Market Share of Major Players
Table 8: Market Access, Forecasts and Profile Of Annual Payment Percentages, UK, 2014-2018
Table 9: Patent Fees ($), 2018, UK
Table 10: Trademark Fees ($), 2018, UK
Table 11: Clinical Trials Application Fees ($), 2018, UK
Table 12: Clinical Trials Application Fees ($) for Medical Devices, 2018, UK
Table 13: Trade Associations, UK
Table 14: Trade Fairs, UK

List of Figures
Figure 1: Pharmaceutical Market, UK, Revenue, 2015-2022
Figure 2: Medical Device Market, UK, Revenue, 2015-2020
Figure 3: UK Brexit Timeline, UK, 2018
Figure 4: Number of Deals (2017-2018)
Figure 5: 2017-2018 Deal Overview By Region
Figure 6: Country Profile, UK, 2018
Figure 7: Pharmaceutical Market, UK, Revenue, 2010-2017
Figure 8: Pharmaceutical Market, UK, Revenue Forecast, 2018-2022
Figure 9: Pharmaceutical Market, UK, Pharmaceutical Exports
Figure 10: Pharmaceutical Market, UK, Top Export Partners
Figure 11: Pharmaceutical Market, UK, Pharmaceutical Imports
Figure 12: Pharmaceutical Market, UK, Top Import Partners
Figure 13: Pharmaceutical Market, UK, Supply Channels
Figure 14: Pharmaceutical Market, UK, Sales of OTC drugs by Major Therapeutic Segments, 2018
Figure 15: Pharmaceutical Market, UK, Sales of Patented Drug Products by Major Therapeutic Class, 2016
Figure 16: Pharmaceutical Market, UK, Sales of Patented Drug Products by Major Therapeutic Class ($bn), 2016
Figure 17: Pharmaceutical Market, UK, Major Players
Figure 18: Medical Device Market, UK, Revenue, 2015-2020
Figure 19: Medical Device Market, UK, Revenue Forecast, 2021-2025
Figure 20: Medical Device Market, UK, Revenue by Segment, 2017
Figure 21: InVitro Diagnostics Devices Market, UK, Revenue
Figure 22: InVitro Diagnostics Devices Market, UK, Market Share of Major Players
Figure 23: Ophthalmic Devices Market, UK, Revenue
Figure 24: Ophthalmic Devices Market, UK, Market Share of Major Players
Figure 25: Cardiovascular Devices Market, UK, Revenue
Figure 26: Cardiovascular Devices Market, UK, Market Share of Major Players
Figure 27: Wound Care Devices Market, UK, Revenue
Figure 28: Wound Care Devices Market, UK, Market Share of Major Players
Figure 29: Orthopedic Devices Market, UK, Revenue
Figure 30: Orthopedic Devices Market, UK, Market Share of Major Players
Figure 31: Diagnostic Market, UK, Revenue ($bn), 2015-2020
Figure 32: Diagnostic Market, UK, Revenue Forecast ($bn), 2021-2025
Figure 33: Medical Device Market, UK, Revenue of Major Players, 2016
Figure 34: Deal Value and Deal Count, Pharmaceutical Market, UK, 2017-2018
Figure 35: Deal Value and Deal Count Quarterly, Pharmaceutical Market, UK, 2017-2018
Figure 36: Deal Value and Deal Count Sub-types, Pharmaceutical Market, UK, 2017-2018
Figure 37: Top Five Therapy Area by Deal Value, Pharmaceutical Market, UK, 2017-2018
Figure 38: Top Five Therapy Area by Deal Number, Pharmaceutical Market, UK, 2017-2018
Figure 39: M&A Deals by Therapy Area, Pharmaceutical Market, UK, 2017-2018
Figure 40: Venture Financing Deals by Therapy Area, Pharmaceutical Market, UK, 2017-2018
Figure 41: Private Equity Deals by Therapy Area, Pharmaceutical Market, UK, 2017-2018
Figure 42: Medical Device Market Deals, UK, 2017-2018 (by Deal Value, $m)
Figure 43: Medical Device Market Deals, UK, 2017- 2018 (by Deal Count)
Figure 44: Medical Device Market Deals Share (by Deal Count), UK, 2017-2018
Figure 45: Medical Device Market Deals Share (by Deal Value), UK, 2017-2018
Figure 46: Medical Device, Top Therapy Area by Deal Value, UK, 2017-2018
Figure 47: Medical Device, Top Therapy Area by Deal Number, UK, 2017-2018
Figure 48: M&A Deals by Therapy Area, Medical Device, UK, 2017-2018 (by Value and by Number)
Figure 49: Venture Financing Deals by Therapy Area, Medical Device, UK, 2017-2018 (by Value and by Number)
Figure 50: Private Equity Deals by Therapy Area, Medical Device, UK, 2017-2018 (by Value and by Number)
Figure 51: Healthcare Market, UK, Overview of Health System, 2018
Figure 52: Overview of Finance Flow, UK, 2018
Figure 53: NHS Departmental Expenditure Limit ($bn), UK, 2015-2021
Figure 54: Market Access, Reimbursement Schemes, UK, 2016
Figure 55: OOP Expenditure (% of Total Expenditure on Health), UK, 2010-2017
Figure 56: Annual Average Rates of Price Change (%), Medicines Price Index, UK, 2010-2017
Figure 57: Market Access, MHRA Structure, UK, 2018
Figure 58: Centralized Procedure, UK, 2018
Figure 59: Centralized Procedure, EU, 2018
Figure 60: Decentralized Procedure, EU, 2018
Figure 61: Mutual Recognition Procedure, UK, 2018
Figure 62: Life Cycle of Medical Device, UK, 2018
Figure 63: Conformity Assessment of Class I Medical Devices, EU, 2018
Figure 64: Conformity Assessment of Class IIa Medical Devices, EU, 2018
Figure 65: Conformity Assessment of Class IIb Medical Devices, EU, 2018
Figure 66: Conformity Assessment of Class III Medical Devices, EU, 2018
Figure 67: Licensing Procedure for Pharmaceutical Manufacturing, UK, 2018
Figure 68: Patent Approval Process, UK, 2018
Figure 69: European Patent Approval Process, EU, 2017
Figure 70: Unitary Patent Approval Process, EU, 2017
Figure 71: Trademark Approval Process, UK, 2018
Figure 72: Clinical Trial Authorization (CTA) Application Flowchart, 2017, UK
Figure 73: Market Access, UK, Clinical Trial Regulation Process for Medical Devices, 2018
Figure 74: Market Access, Regulatory Changes in the UK Before and After Brexit, 2018
Figure 75: Number of Hospitals, UK, 2010-2017
Figure 76: Diagnostic Equipment (per Million Population), UK, 2010-2017
Figure 77: Hospital Beds (per 1,000 Population), UK
Figure 78: Psychiatric Hospital Beds (per 1,000 Population), UK
Figure 79: Life Expectancy, 2010-2017, UK
Figure 80: Immunization Rate (%), 2010-2017, UK
Figure 81: PM2.5 (μg per m3), UK, 2010-2017
Figure 82: CO2 Emissions (Million Tons), UK, 2010-2017
Figure 83: Physicians (per 1,000 Population), UK, 2010-2016
Figure 84: Nurses (per 1,000 Population), UK, 2010-2016
Figure 85: Dentists (per 1,000 Population), UK, 2010-2016
Figure 86: Pharmacists (per 1,000 Population), UK, 2010-2016
Figure 87: Major Causes of Mortality (per 1,000 Population), UK, 2016
Figure 88: Major Causes of Male Mortality, UK, 2016
Figure 89: Major Causes of Female Mortality, UK, 2016
Figure 90: Disability-Adjusted Life Years by Major Disease (‘000), UK, 2016
Figure 91: Healthcare Expenditure as Percentage of GDP (%), UK, 2010-2017
Figure 92: Public-Private Share (%), UK, 2010-2017
Figure 93: Major Components of Healthcare Spending (%), UK, 2016
Figure 94: Opportunities and Challenges, UK 147
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
A growing disease burden, universal healthcare coverage, and good access to healthcare facilities provide the necessary momentum for the growth of the UK healthcare market; but increasing use of generics and government cost-cutting measures to reduce expenditure are restricting growth.

The pharmaceutical market in the UK was worth approximately $24 billion in 2012 and is projected to reach approximately $31.7 billion by 2020 at a Compound Annual Growth Rate (CAGR) of 3.5% (OECD, 2011). The segments that dominated the market in 2012 were Central Nervous System (CNS) drugs, cardiovascular drugs, and respiratory system drugs. The UK is one of the most profitable healthcare markets among the European Union (EU) member states.

The prevalence of hypertension has increased from 7.4 million in 2010–2011 to 7.6 million in 2011–2012. The prevalence of depression in people above 18 years of age increased from 4.8 million in 2010–2011 to 5.1 million in 2011–2012. In 2012, the prevalence of diabetes in England increased by 4.5% from 2011. The government has allocated funds to encourage R&D and has implemented campaigns to enhance the prevention and treatment of chronic diseases such as cancer and diabetes.

The UK provides public healthcare to all citizens, approximately 63.2 million people. The National Health Service (NHS) is responsible for the public healthcare sector of the UK. The NHS is the one of the world’s largest healthcare system and provides a wide range of healthcare services to the entire population, such as routine treatments for long-term conditions, transplants, emergency treatment, antenatal screening, and end-of-life care, but charges for dental and optical services. Healthcare coverage is free at the point of need, and funding comes from taxation and is granted to the Department of Health (DH) (NHS, 2013a).

Increasing generic substitution and cost-cutting measures adopted by the government and the NHS have on the other hand had a negative impact on market growth. Price cuts have led to market decline. The UK’s government introduced price cuts on branded medicines of 3.9% in 2009 and 1.9% in 2010 to reduce NHS expenditure (DH, 2008). In 2013, the DH announced plans to cut drug prices by 10–20% on approximately 10% of branded medicines not covered by the voluntary Pharmaceutical Price Regulation Scheme (PPRS) (DH, 2013). Generic substitution by pharmacists was implemented by the NHS in 2009 and has reduced the overall value of the pharmaceutical market.

The medical device market was worth approximately $12 billion in 2012, placing the UK fourth in Europe after Germany, France, and Italy. The market is projected to reach approximately $17.5 billion by 2020 at a CAGR of 4.8%.

In 2012, the major segments of the medical device market in terms of share were ophthalmic devices ($1.4 billion), orthopedic devices ($1.4 billion), wound care management ($1.1 billion), cardiovascular devices ($1.1 billion) and drug delivery devices ($1 billion).

With the availability of reimbursement, advances in medical technology, and growing disease awareness enabling early diagnosis, the medical device market in the UK is expected to grow significantly in the future.

Directive 2007/47/EC amended both the Medical Devices and Active Implantable Medical Devices Directives, and a revision of this Directive came into force in 2010 in order to improve and strengthen regulations.
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/2654490
Adroll
adroll